Switching from MAPK-dependent to MAPK-independent repression of the sodium-iodide symporter in 2D and 3D cultured normal thyroid cells

Molecular and Cellular Endocrinology

Volumn 381, Issue 1-2, 2013, Pages 241-254

  Ingeson Carlsson, Camilla ^a   Nilsson, Mikael ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

EGF; Iodide transport; MAPK; MEK inhibitor; NIS; Thyroid

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; EPIDERMAL GROWTH FACTOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SODIUM IODIDE SYMPORTER; THYROGLOBULIN; THYROTROPIN;

ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GENE REPRESSION; INTRACELLULAR TRANSPORT; IODINATION; NONHUMAN; PRIORITY JOURNAL; THYROID FOLLICLE CELL; THYROID HORMONE SYNTHESIS;

EGF; EMT; EPIDERMAL GROWTH FACTOR; EPITHELIAL TO MESENCHYMAL TRANSITION; ERK1/2; EXTRACELLULAR-SIGNAL REGULATED KINASE 1/2; FBS; FETAL BOVINE SERUM; IGF-1; INSULIN-LIKE GROWTH FACTOR-1; IODIDE TRANSPORT; LY294002; MAPK; MAPK KINASE; MEK; MEK INHIBITOR; MEK1/2 INHIBITOR; MITOGEN-ACTIVATED PROTEIN KINASE; NIS; PAPILLARY THYROID CANCER; PD; PHOSPHOINOSITIDE-3-KINASE; PI3K; PI3K INHIBITOR; POTENTIAL DIFFERENCE; PTC; SODIUM IODIDE SYMPORTER; TER; TG; TGF-BETA; THYROGLOBULIN; THYROID; THYROID STIMULATION HORMONE (THYROTROPIN); TRANSEPITHELIAL RESISTANCE; TRANSFORMING GROWTH FACTOR-BETA; TSH; U0126;

ANIMALS; BIOLOGICAL TRANSPORT; BUTADIENES; CELL CULTURE TECHNIQUES; CELL DIFFERENTIATION; CELLS, CULTURED; CULTURE MEDIA, SERUM-FREE; EPIDERMAL GROWTH FACTOR; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION; GENE SILENCING; IODIDES; MAP KINASE KINASE KINASES; MAP KINASE SIGNALING SYSTEM; NITRILES; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; RNA, MESSENGER; SUS SCROFA; SYMPORTERS; THYROID GLAND;

EID: 84884125926     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2013.08.006     Document Type: Article

References (46)

1. Bernier-Valentin F., Trouttet-Masson S., Rabilloud R., Selmi-Ruby S., Rousset B. Three-dimensional organization of thyroid cells into follicle structures is a pivotal factor in the control of sodium/iodide symporter expression. Endocrinology 2006, 147:2035-2042.
2. Bissell M.J., Rizki A., Mian I.S. Tissue architecture: the ultimate regulator of breast epithelial function. Curr. Opin. Cell. Biol. 2003, 15:753-762.
3. Chakravarty D., Santos E., Ryder M., Knauf J.A., Liao X.H., West B.L., Bollag G., Kolesnick R., Thin T.H., Rosen N., et al. Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. J. Clin. Invest. 2011, 121:4700-4711.
4. Clement S., Refetoff S., Robaye B., Dumont J.E., Schurmans S. Low TSH requirement and goiter in transgenic mice overexpressing IGF-I and IGF-Ir receptor in the thyroid gland. Endocrinology 2001, 142:5131-5139.
5. Correia A.L., Bissell M.J. The tumor microenvironment is a dominant force in multidrug resistance. Drug. Resist. Updat. 2012, 15:39-49.
6. Coulonval K., Vandeput F., Stein R.C., Kozma S.C., Lamy F., Dumont J.E. Phosphatidylinositol 3-kinase, protein kinase B and ribosomal S6 kinases in the stimulation of thyroid epithelial cell proliferation by cAMP and growth factors in the presence of insulin. Biochem. J. 2000, 348(Pt 2):351-358.
7. Di Matola T., Mueller F., Fenzi G., Rossi G., Bifulco M., Marzano L.A., Vitale M. Serum withdrawal-induced apoptosis in thyroid cells is caused by loss of fibronectin-integrin interaction. J. Clin. Endocrinol. Metab. 2000, 85:1188-1193.
8. Ekholm R. Iodination of thyroglobulin. An intracellular or extracellular process?. Mol. Cell. Endocrinol. 1981, 24:141-163.
9. Ekholm R., Bjorkman U. Glutathione peroxidase degrades intracellular hydrogen peroxide and thereby inhibits intracellular protein iodination in thyroid epithelium. Endocrinology 1997, 138:2871-2878.
10. Ericson L.E. Exocytosis and endocytosis in the thyroid follicle cell. Mol. Cell. Endocrinol. 1981, 22:1-24.
11. Ericson L.E., Nilsson M. Effects of insulin-like growth factor I on growth, epithelial barrier and iodide transport in polarized pig thyrocyte monolayers. Eur. J. Endocrinol. 1996, 135:118-127.
12. Ericson L.E., Nilsson M. Deactivation of TSH receptor signaling in filter-cultured pig thyroid epithelial cells. Am. J. Physiol. Endocrinol. Metab. 2000, 278:E611-619.
13. Garbi C., Nitsch L., Wollman S.H. Embedding in a collagen gel stabilizes the polarity of epithelial cells in thyroid follicles in suspension culture. Exp. Cell Res. 1984, 151:458-465.
14. Garcia B., Santisteban P. PI3K is involved in the IGF-I inhibition of TSH-induced sodium/iodide symporter gene expression. Mol. Endocrinol. 2002, 16:342-352.
15. Grande M., Franzen A., Karlsson J.O., Ericson L.E., Heldin N.E., Nilsson M. Transforming growth factor-beta and epidermal growth factor synergistically stimulate epithelial to mesenchymal transition (EMT) through a MEK-dependent mechanism in primary cultured pig thyrocytes. J. Cell. Sci. 2002, 115:4227-4236.
16. Hebrant A., van Staveren W.C., Delys L., Solis D.W., Bogdanova T., Andry G., Roger P., Dumont J.E., Libert F., Maenhaut C. Long-term EGF/serum-treated human thyrocytes mimic papillary thyroid carcinomas with regard to gene expression. Exp. Cell. Res. 2007, 313:3276-3284.
17. Ho A.L., Grewal R.K., Leboeuf R., Sherman E.J., Pfister D.G., Deandreis D., Pentlow K.S., Zanzonico P.B., Haque S., Gavane S., et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N. Engl. J. Med. 2013, 368:623-632.
18. Knauf J.A., Ma X., Smith E.P., Zhang L., Mitsutake N., Liao X.H., Refetoff S., Nikiforov Y.E., Fagin J.A. Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res. 2005, 65:4238-4245.
19. Knauf J.A., Sartor M.A., Medvedovic M., Lundsmith E., Ryder M., Salzano M., Nikiforov Y.E., Giordano T.J., Ghossein R.A., Fagin J.A. Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGFbeta signaling. Oncogene 2011, 30:3153-3162.
20. Leboeuf R., Baumgartner J.E., Benezra M., Malaguarnera R., Solit D., Pratilas C.A., Rosen N., Knauf J.A., Fagin J.A. BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines. J. Clin. Endocrinol. Metab. 2008, 93:2194-2201.
21. Levin V.A., Panchabhai S.C., Shen L., Kornblau S.M., Qiu Y., Baggerly K.A. Different changes in protein and phosphoprotein levels result from serum starvation of high-grade glioma and adenocarcinoma cell lines. J. Proteome Res. 2010, 9:179-191.
22. Liu D., Hu S., Hou P., Jiang D., Condouris S., Xing M. Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant. Clin. Cancer Res. 2007, 13:1341-1349.
23. Liu Z., Hou P., Ji M., Guan H., Studeman K., Jensen K., Vasko V., El-Naggar A.K., Xing M. Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. J. Clin. Endocrinol. Metab. 2008, 93:3106-3116.
24. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001, 25:402-408.
25. Mitsutake N., Knauf J.A., Mitsutake S., Mesa C., Zhang L., Fagin J.A. Conditional BRAFV600E expression induces DNA synthesis, apoptosis, dedifferentiation, and chromosomal instability in thyroid PCCL3 cells. Cancer Res. 2005, 65:2465-2473.
26. Montero-Conde C., Ruiz-Llorente S., Dominguez J.M., Knauf J.A., Viale A., Sherman E.J., Ryder M., Ghossein R.A., Rosen N., Fagin J.A. Relief of Feedback Inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas. Cancer Discov. 2013, 3:520-533.
27. Nikiforova M.N., Kimura E.T., Gandhi M., Biddinger P.W., Knauf J.A., Basolo F., Zhu Z., Giannini R., Salvatore G., Fusco A., et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J. Clin. Endocrinol. Metab. 2003, 88:5399-5404.
28. Nilsson M. Actions of epidermal growth factor and its receptor in the thyroid. Trends Endocrinol. Metab. 1995, 6:175-182.
29. Nilsson M., Ericson L.E. Effects of epidermal growth factor on basolateral iodide uptake and apical iodide permeability in filter-cultured thyroid epithelium. Endocrinology 1994, 135:1428-1436.
30. Nilsson M., Ericson L.E. Effects of epidermal growth factor and phorbol ester on thyroid epithelial integrity. Exp. Cell Res. 1995, 219:626-639.
31. Nilsson M., Bjorkman U., Ekholm R., Ericson L.E. Iodide transport in primary cultured thyroid follicle cells: evidence of a TSH-regulated channel mediating iodide efflux selectively across the apical domain of the plasma membrane. Eur. J. Cell Biol. 1990, 52:270-281.
32. Nitsch L., Wollman S.H. Ultrastructure of intermediate stages in polarity reversal of thyroid epithelium in follicles in suspension culture. J. Cell. Biol. 1980, 86:875-880.
33. Norden M.M., Larsson F., Tedelind S., Carlsson T., Lundh C., Forssell-Aronsson E., Nilsson M. Down-regulation of the sodium/iodide symporter explains 131I-induced thyroid stunning. Cancer Res. 2007, 67:7512-7517.
34. Pedrinola F., Rubio I., Santos C.L., Medeiros-Neto G. Overexpression of epidermal growth factor and epidermal growth factor-receptor mRNAs in dyshormonogenetic goiters. Thyroid 2001, 11:15-20.
35. Pirkmajer S., Chibalin A.V. Serum starvation: caveat emptor. Am. J. Physiol. Cell Physiol. 2011, 301:C272-279.
36. Pohl V., Roger P.P., Christophe D., Pattyn G., Vassart G., Dumont J.E. Differentiation expression during proliferative activity induced through different pathways: in situ hybridization study of thyroglobulin gene expression in thyroid epithelial cells. J. Cell. Biol. 1990, 111:663-672.
37. Poulikakos P.I., Solit D.B. Resistance to MEK inhibitors: should we co-target upstream?. Sci. Signal. 2011, 4:16.
38. Riesco-Eizaguirre G., Rodriguez I., De la Vieja A., Costamagna E., Carrasco N., Nistal M., Santisteban P. The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer. Cancer Res. 2009, 69:8317-8325.
39. Roger P.P., Van Heuverswyn B., Lambert C., Reuse S., Vassart G., Dumont J.E. Antagonistic effects of thyrotropin and epidermal growth factor on thyroglobulin mRNA level in cultured thyroid cells. Eur. J. Biochem. 1985, 152:239-245.
40. Roger P., Taton M., Van Sande J., Dumont J.E. Mitogenic effects of thyrotropin and adenosine 3',5'-monophosphate in differentiated normal human thyroid cells in vitro. J. Clin. Endocrinol. Metab. 1988, 66:1158-1165.
41. Schlumberger M., Lacroix L., Russo D., Filetti S., Bidart J.M. Defects in iodide metabolism in thyroid cancer and implications for the follow-up and treatment of patients. Nat. Clin. Pract. Endocrinol. Metab. 2007, 3:260-269.
42. Selmi-Ruby S., Watrin C., Trouttet-Masson S., Bernier-Valentin F., Flachon V., Munari-Silem Y., Rousset B. The porcine sodium/iodide symporter gene exhibits an uncommon expression pattern related to the use of alternative splice sites not present in the human or murine species. Endocrinology 2003, 144:1074-1085.
43. Taton M., Lamy F., Roger P.P., Dumont J.E. General inhibition by transforming growth factor beta 1 of thyrotropin and cAMP responses in human thyroid cells in primary culture. Mol. Cell. Endocrinol. 1993, 95:13-21.
44. Villanueva J., Vultur A., Herlyn M. Resistance to BRAF inhibitors: unraveling mechanisms and future treatment options. Cancer Res. 2011, 71:7137-7140.
45. Waters M.J., Tweedale R.C., Whip T.A., Shaw G., Manley S.W., Bourke J.R. Dedifferentiation of cultured thyroid cells by epidermal growth factor: some insights into the mechanism. Mol. Cell. Endocrinol. 1987, 49:109-117.
46. Weigelt B., Lo A.T., Park C.C., Gray J.W., Bissell M.J. HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment. Breast Cancer Res. Treat. 2010, 122:35-43.